SNY (Sanofi) Cash Ratio : 0.23 (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Sanofi's Cash Ratio for the quarter that ended in Jun. 2024 was 0.23.

Sanofi has a Cash Ratio of 0.23. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Sanofi's Cash Ratio or its related term are showing as below:

SNY' s Cash Ratio Range Over the Past 10 Years
Min: 0.23 Med: 0.5 Max: 0.85
Current: 0.23

During the past 13 years, Sanofi's highest Cash Ratio was 0.85. The lowest was 0.23. And the median was 0.50.

SNY's Cash Ratio is ranked worse than
70.85% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 0.57 vs SNY: 0.23

Sanofi Cash Ratio Historical Data

The historical data trend for Sanofi's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Cash Ratio Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Ratio

Get a 7-Day Free Trial

0.48

0.52

0.56

0.37

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash Ratio	Get a 7-Day Free Trial															0.31	0.56	0.32	0.37	0.23

Competitive Comparison of Sanofi's Cash Ratio

For the Drug Manufacturers - General subindustry, Sanofi's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi's Cash Ratio falls into.

Sanofi Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Sanofi's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	9792.803	/	26398.037
	=	0.37

Sanofi's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	7314.316	/	32321.851
	=	0.23

Sanofi (NAS:SNY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

Sanofi Cash Ratio Related Terms

Thank you for viewing the detailed overview of Sanofi's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Cash Ratio

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.